Journal of Rheumatic Diseases

Cited by CrossRef (13)

  1. Y. H. Lee, G. G. Song. Anifrolumab for the treatment of active systemic lupus erythematosus: a meta-analysis of randomized controlled trials. Z Rheumatol 2021;80:988
    https://doi.org/10.1007/s00393-020-00928-7
  2. V Colmenares, A Hedman, A Hesslow, B Wahlin, A Södergren. Cohort study of serological biomarkers for interstitial lung disease in patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology 2024;53:386
    https://doi.org/10.1080/03009742.2024.2413238
  3. Y. H. Lee, G. G. Song. Comparative efficacy and safety of secukinumab and ixekizumab in patients with active ankylosing spondylitis. Z Rheumatol 2021;80:776
    https://doi.org/10.1007/s00393-020-00837-9
  4. Yoon-Kyoung Sung, Young Ho Lee. Placebo and nocebo responses in randomized controlled trials of non-tumor necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumor necrosis factor inhibitors: A meta-analysis. Z Rheumatol 2023;82:59
    https://doi.org/10.1007/s00393-021-01047-7
  5. Kwang Jin Ko, Gahyun Kim, Hyun Hwan Sung, Woong-Yang Park, Kyu-Sung Lee. Potential Role of Macrophage Polarization in the Progression of Hunner-Type Interstitial Cystitis. IJMS 2024;25:778
    https://doi.org/10.3390/ijms25020778
  6. Izabela Kokot, Sylwester Mazurek, Agnieszka Piwowar, Renata Sokolik, Kamil Rodak, Monika Kacperczyk, Roman Szostak, Przemysław Cuprych, Lucyna Korman, Ewa Maria Kratz. Comparative profiling of serum biomarkers and ATR-FTIR spectroscopy for differential diagnosis of patients with rheumatoid and psoriatic arthritis − a pilot study. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 2024;321:124654
    https://doi.org/10.1016/j.saa.2024.124654
  7. Y. H. Lee, G. G. Song. Janus kinase inhibitors for treating active ankylosing spondylitis: a meta-analysis of randomized controlled trials. Z Rheumatol 2022;81:71
    https://doi.org/10.1007/s00393-020-00948-3
  8. Y.-K. Sung, Y. H. Lee. Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naïve patients with rheumatoid arthritis. Z Rheumatol 2021;80:889
    https://doi.org/10.1007/s00393-020-00889-x
  9. José David Tadeo Esparza-Díaz, Jorge Ivan Gamez-Nava, Laura Gonzalez-Lopez, Ana Miriam Saldaña-Cruz, Andrea Carolina Machado-Sulbaran, Alberto Beltrán-Ramírez, Miryam Rosario Guillén-Medina, Ana Gabriela Flores-Vargas, Edsaúl Emilio Pérez-Guerrero. Elevated Serum Levels of YKL-40, YKL-39, and SI-CLP in Patients with Treatment Failure to DMARDs in Patients with Rheumatoid Arthritis. Biomedicines 2024;12:1406
    https://doi.org/10.3390/biomedicines12071406
  10. Dong Liu, Xin Hu, Xiao Ding, Ming Li, Lei Ding. Inflammatory Effects and Regulatory Mechanisms of Chitinase-3-like-1 in Multiple Human Body Systems: A Comprehensive Review. IJMS 2024;25:13437
    https://doi.org/10.3390/ijms252413437
  11. Stefano Floro, Tiziana Carandini, Anna Margherita Pietroboni, Milena Alessandra De Riz, Elio Scarpini, Daniela Galimberti. Role of Chitinase 3–like 1 as a Biomarker in Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm 2022;9
    https://doi.org/10.1212/NXI.0000000000001164
  12. Yoon-Kyoung Sung, Young Ho Lee. Placebo and nocebo responses in randomized controlled trials of Janus kinase inhibitor monotherapy for rheumatoid arthritis. Z Rheumatol 2022;81:430
    https://doi.org/10.1007/s00393-021-00969-6
  13. Yoon‐Kyoung Sung, Young Ho Lee. Comparative effectiveness and safety of non‐tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta‐analysis of randomized controlled trials. J Clin Pharm Ther 2021;46:984
    https://doi.org/10.1111/jcpt.13380